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Natural infection of humans with human T-cell lymphotropic virus type I (HTLV-I) and of old world nonhuman primates with
the simian counterpart, STLV-I, is associated with development of neoplastic disease in a small percentage of individuals
after long latent periods. HTLV-I is also the etiologic agent of a more rapidly progressive neurologic disease, HTLV-I-
associated myelopathy/tropical spastic paraparesis (HAM/TSP). Macaques have been used experimentally in studies to
evaluate HTLV-I candidate vaccines for efficacy, but no evidence of disease was observed. Here we report experimental
infection of pig-tailed macaques with STLV-I(sm) and HTLV-I(ACH), both of which were associated with a disease syndrome
characterized by rapid onset, hypothermia, lethargy, and death within hours to days. Other pathologic sequelae included
diarrhea, rash, bladder dysfunction, weight loss, and, in one animal, arthropathy. Both retroviruses were detected in the
central nervous systems of some animals, either by culture or by direct antigen capture for p19 Gag in cerebrospinal fluid.
Although virus was recovered throughout infection from peripheral blood mononuclear cells (PBMC), all infected macaques
maintained low antiviral antibody titers and stable proviral burdens, which generally ranged between 10 and 100 copies per
106 PBMC. However, of 13 macaques infected with HTLV-I(ACH) or STLV-I(sm), seven animals (54%) died between 35 weeks
and 4 12 years after infection. This unexpected high mortality within a relatively short time suggests that infection of pig-tailed© 2002 Elsevier Science (USA)
INTRODUCTION
Infection of humans with human T-cell lymphotropic
virus type I (HTLV-I) is endemic in the Caribbean, Africa,
Japan, and Melanesia (Blattner et al., 1982; Hinuma et al.,
1982; Hunsmann et al., 1983; Delaporte et al., 1989;
Murphy et al., 1991; Gessain et al., 1993). Of individuals
infected with HTLV-I, less than 5% develop adult T-cell
leukemia (ATL) or a chronic demyelinating disease,
HTLV-associated myelopathy/tropical spastic parapare-
sis (HAM/TSP) (Poiesz et al., 1980; Hinuma et al., 1981;
Yoshida et al., 1982; Gessain et al., 1985; Rodgers-John-
son et al., 1985; Bartholomew et al., 1986; Osame et al.,
1986; Vernant et al., 1987; Murphy et al., 1989). Because
healthy carriers of the virus and those with cutaneous
malignancies can be serologically negative, identifying
HTLV-I-infected individuals by standard antibody ELISA
is not always definitive (Daenke et al., 1994; Zehender et
al., 1996). Furthermore, proviruses in peripheral blood
lymphocytes of some infected individuals remain latent
or express only those parts of the HTLV-I genome, such
as the tax gene, that are associated with disease (Berne-
man et al., 1992; Ghosh et al., 1994; Richardson et al.,0042-6822/02 $35.00
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3641997). This limited gene expression can be the result of
a high proportion of HTLV-I DNA existing in the host
genome as defective proviruses (Korber et al., 1991;
Daenke et al., 1994; Shuh et al., 1999). Because some
individuals do not seroconvert and only a small percent-
age of infected individuals develop disease, sometimes
as long as 20 to 30 years after infection, identification of
infected people typically occurs after several years. As a
result, cross-sectional studies of HTLV-I-infected individ-
uals are of limited use for studying early events that
might influence HTLV-I pathogenesis and, therefore, ini-
tial host responses have not been characterized.
Until recently, the use of animal models to study the
pathogenesis of HTLV-I-related disease has been limited
to transgenic or SCID mice or other small mammals,
such as rabbits and rats, that can be persistently infected
with the virus (Miyoshi et al., 1985; Ishiguro et al., 1992;
Lairmore et al., 1992; Feuer et al., 1993; Ruddle et al.,
1993). Cutaneous lymphoproliferative disease has been
reported in HTLV-I-infected rabbits (Simpson et al., 1996).
There is also evidence of inflammatory arthropathy and
leukemia in HTLV-I tax-transgenic mice and leukemia in
SCID mice (Iwakura et al., 1991; Feuer et al., 1993; Ruddle
et al., 1993; Grossman et al., 1995, 1997; Saggioro et al.,
1997). WKA rats infected with HTLV-I develop clinicalmacaques might be a useful model for studying immune re
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symptoms similar to those of HAM/TSP and inflammatory
arthropathy in humans (Ishiguro et al., 1992; Kushida etsponse
al., 1994; Kira et al., 1997). The availability of inbred and
transgenic rats has made the rat model particularly use-
ful for addressing questions related to genetic suscepti-
bility to infection and disease progression.
Experimental infection of nonhuman primates was first
reported in the late 1980s by Nakamura et al. (1986);
these investigators showed that both cynomolgus ma-
caques (Macaca fascicularis) and squirrel monkeys
(Saimiri sciureus) could be persistently infected. How-
ever, no signs of disease were observed during more
than 2 years of evaluation. Both cynomolgus and squirrel
monkeys were used subsequently in vaccine studies
(Nakamura et al., 1987; Ibuki et al., 1997; Kazanji et al.,
2001). The only studies to provide a detailed analysis of
virologic and immunologic events early after infection
utilized the squirrel monkey model (Kazanji et al., 1997,
2000). Again, throughout 4 years of follow-up, no evi-
dence of disease was seen. Furthermore, these primates
are new-world, not old-world, monkeys, the latter of
which are natural hosts for STLV-I, the simian counter-
part of HTLV-I (Fultz, 1994). In addition, monoclonal anti-
body reagents to some cell-surface antigens, such as
CD8, are not available for use in the squirrel monkey
model.
For maximum usefulness, an ideal animal model for
HTLV-I pathogenesis should be one that includes the de-
velopment of virus-specific immune responses coupled
with HTLV-I-associated pathology. Differences between the
immune systems of rodents and humans cannot be ig-
nored, particularly in models of HAM/TSP, because im-
mune-mediated mechanisms appear to contribute to its
development (Moore et al., 1989; Levin et al., 1997). We
previously showed that STLV-I(sm), which was isolated
from a naturally infected sooty mangabey (Cercocebus
atys) (Fultz et al., 1997), establishes long-term infections
with seroconversion in pig-tailed macaques (M. nemest-
rina) (Fultz et al., 1999). In this earlier study, macaques were
infected with both simian immunodeficiency virus (SIV) and
STLV-I(sm) to test the hypothesis that coinfection results in
enhanced progression to SIV-related disease. Although
there was no evidence of accelerated progression to AIDS,
STLV-I(sm)-specific antibody titers were elevated in ma-
caques infected with both viruses when compared to anti-
body titers in those animals infected with only STLV-I(sm).
One dually infected macaque that died at 55 weeks after
inoculation of STLV-I(sm) had evidence of abnormal lym-
phocyte activation with 50% of peripheral blood mononu-
clear cells (PBMC) expressing CD25. This finding sug-
gested onset of lymphoproliferative disease and indicated
that a more thorough evaluation of the natural history of
STLV-I(sm) infection of pig-tailed macaques was warranted.
In this article, we provide a more detailed analysis of
virologic and immunologic parameters associated with
persistent infection, not only with STLV-I(sm), but also
with HTLV-I(ACH), a chimeric molecular clone composed
of coding sequences from HTLV-I isolate CH plus long-
terminal repeats and the 5 end of gag from the proto-
typic strain ATK (Kimata et al., 1994). All isolates of STLV-I
and HTLV-I, regardless of species of origin, are collec-
tively referred to as the primate T-cell lymphotropic vi-
ruses (PTLV). Throughout this article, PTLV will be used
when referring to generalizations and aspects of the
study that apply to both STLV-I(sm) and HTLV-I(ACH) or to
both STLV-I(sm)- and HTLV-I(ACH)-infected animals.
RESULTS
Establishment of PTLV persistent infections
As indicated above, we previously showed that long-
term persistent infections with STLV-I(sm) were readily
established in three pig-tailed macaques as well as in 10
macaques infected with both STLV-I(sm) and SIV-PBj14-
bcl1 (Fultz et al., 1999). Infections with STLV-I(sm) only
were characterized by seroconversion and, using stan-
dard cocultivation techniques, the ability to isolate virus
from peripheral blood of the three animals on 55.3, 72.7,
and 81.8% of attempts. To determine whether HTLV-I also
could establish persistent infections with seroconversion
and long-term maintenance of infected lymphocytes in
blood and other tissues, initially six macaques were
inoculated intravenously with a pig-tailed macaque cell
line (PTMach) persistently infected with the molecular
clone HTLV-I(ACH). Subsequently, four additional ani-
mals were inoculated with PTMach cells. Virus was iso-
lated from PBMC from all animals 3 to 6 weeks after
inoculation; however, to ensure that the infections were
sustained, all 10 animals received a second intravenous
inoculation, either 9 (eight animals) or 19 (two animals)
weeks after the first one.
Mortality
Pig-tailed macaques infected with STLV-I(sm) or HTLV-
I(ACH) died earlier than or at times comparable to those
of macaques infected with both STLV-I(sm) and SIV-
PBj14-bcl1 or with SIV-PBj14-bcl1 only (Fultz et al., 1999),
which was unexpected (Fig. 1). HTLV-I(ACH)-infected
macaques appeared to progress to overt disease more
rapidly than those infected only with STLV-I(sm), with 4 of
the 10 animals dying between 35 and 82 weeks after
inoculation. The first death among animals infected with
STLV-I(sm) alone did not occur until week 111, and all
three STLV-I(sm)-infected macaques had died by 224
weeks. Taken together, the mortality of these two groups
was 54% in less than 4 12 years. Such abnormally high
mortality rates have never been observed among normal
macaques housed at our institution for comparable or
longer periods of time.
PTLV-associated pathology
Immediately before end-stage disease, some animals
had intermittent diarrhea, rash, and/or weight loss, but
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the majority did not appear to have life-threatening con-
ditions (Fig. 2, Table 1). Terminal disease in PTLV-in-
fected animals was characterized by rapid onset of leth-
argy, hypothermia (35.5°C), loss of appetite, and, in
some extreme cases, loss of consciousness. The rapid-
ity with which animals progressed to extreme morbidity
was unusual; an animal could appear well, then develop
the acute syndrome and die within 24 to 48 h. Four of the
macaques were lymphopenic at death, whereas two
animals (3FA and AP1T) had extensive mesenteric
lymphadenopathy with extremely large colonic lymph
nodes. Of these two animals, macaque 3FA had experi-
enced chronic diarrhea and was diagnosed with
Trichomonas in fecal samples 2 weeks before euthana-
sia. In contrast, macaque AP1T was euthanized with no
overt signs of disease when the study was terminated.
At necropsy four of nine animals inoculated with either
STLV-I(sm) (TC1, P023, P020) or HTLV-I(ACH) (3EC) had
apparent bladder dysfunction, characterized by disten-
sion with residual urine, despite the tendency of most
animals to void completely immediately after intramus-
cular injection of anesthesia. This condition is one of the
clinical hallmarks associated with HAM/TSP (Komine et
al., 1989; Saito et al., 1991; Walton and Kaplan, 1993;
Hattori et al., 1994). Although two (P020 and P023) of the
three STLV-I(sm)-infected animals that had evidence of
bladder dysfunction were also infected with SIV-PBj14-
bcl1; none of six animals infected only with SIV-PBj14-
bcl1 had a similar condition.
At 33 weeks after infection, one animal (AD7D) in-
fected with HTLV-I(ACH) was diagnosed with arthritis in
the metatarsals of the left foot. The joints of the affected
limb were inflamed with considerable soft-tissue swell-
ing and movement was severely restricted. Radiographs
revealed a decrease in cortical bone density accompa-
nied by generation of osteophytes (Fig. 3). The diagnosis
of arthritis in this animal was coincident with an episode
of thrombocytosis: platelet counts increased from the
normal range (200,000 to 400,000/l) to greater than 1 
106/l of blood. For several days following these obser-
vations, macaque AD7D had moderate diarrhea (with
blood) and was treated for dehydration. Total blood cal-
cium at this time was slightly below normal (8.2 mg/dl),
whereas serum lactate dehydrogenase was slightly ele-
vated (248 U/L). A bone marrow biopsy was performed 3
days before death, which occurred on a weekend, and
precluded further evaluation of tissues. Of interest, cells
were pelleted from the bone marrow sample, and the
resulting fluid contained HTLV-I(ACH) p19 Gag by ELISA,
indicating cell-free virus was present.
PTLV-infected animals TC1 and AT4X had persistent
rash. Within 2 weeks after the first HTLV-I(ACH) inocula-
tion, macaque AT4X developed a rash over the chest,
neck, and abdomen, which spread to the legs and un-
derarms before clearing slightly at 6 weeks. Following
the second inoculation of virus at 9 weeks, the rash
became severe, indicating that it probably was caused
by HTLV-I(ACH). The chest and abdomen of this animal
were inflamed consistently through week 29, and the
rash remained diffuse over this area when the animal
was euthanized at 85 weeks after infection.
Histopathology
Paraffinized tissue sections from the brain and/or spi-
nal cord of PTLV-infected animals revealed no definitive
or consistent evidence of disease. In the cerebral cortex
from HTLV-I(ACH)-infected macaque 3EC there was evi-
dence of nucleosis or abnormal proliferation of nuclei,
FIG. 1. PTLV-associated mortality of pig-tailed macaques infected with STLV-I(sm) or HTLV-I(ACH) (dashed lines). Two groups of six (group 1) and
four (group 2) macaques were infected with HTLV-I(ACH) at different times, as indicated by the two survival curves. These animals were not infected
for as long as the STLV-I(sm) group. Since three of the six macaques in group 1 and three of the four macaques in group 2 were euthanized, beginning
at weeks 129 and 85, respectively, with no life-threatening signs of disease, the curve does not include their times of death. Mortality of 10 macaques
infected with both STLV-I(sm) and SIV-PBj14-bcl1 (Fultz et al., 1999) is shown for comparison.
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but no evidence for microglial activation. In the cerebrum
of two animals, 3EC and TA7, scattered mild vacuolation
and an increase in perivascular spaces was observed,
suggesting edema. Luxol fast blue stain of spinal cord
and brain sections from six PTLV-infected macaques did
not reveal any evidence of demyelination. In macaque
TB7, infected with STLV-I(sm), microglial activation and
diffuse areas of neuronal dropout were noted in the
cerebellum. The cerebral cortex of macaque TB7 con-
tained what appeared to be either an increase in satellite
cells or an accumulation of glial cells around neurons.
There was no evidence of gliosis or perivascular cuffing
in the brain stem.
Liver, lung, kidney, heart, lymphoid tissues, and small
and large intestines from infected macaques also were
evaluated histologically. Lung tissue from macaque TB7
showed some evidence of edema. Liver sections from
three animals (3EC, TB7, and TA7) revealed mild atrophy
of centrilobular hepatocytes. Lymph node sections from
3EC, TA7, and TC1 had increased numbers of histiocytes
FIG. 2. Weight gain and clinical signs of disease in macaques infected with STLV-I(sm) (A) or HTLV-I(ACH) group 1 (B) and group 2 (C). D, diarrhea;
R, rash; B, bladder distension; Bl, bloat; H, hypothermia (35.5°C); A, acute onset disease syndrome; †, death.
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with intracytoplasmic globules. Deposition of amyloid
around vessels was observed in lymph nodes from ma-
caques TA7 and TB7 and in splenic tissue from TB7, 3FN,
and TC1. Despite the observed diarrhea in several ani-
mals, most sections of small and large intestines ap-
peared normal; large intestinal tissues from two animals
TABLE 1
Summary of Clinical Signs of Disease in PTLV-Infected Macaques
Virus Animal Clinical signs Weeksa
STLV-I(sm) TA7 Chronic diarrhea 192
TB7 Chronic bloat, diarrhea, hypothermia (35°C), dehydration, weight loss (25%), hepatitis 111
TC1 Rash, diarrhea, skin lesions on upper thorax, lymphopenia (610 lymphocytes/l), distended
bladder, hypothermia (35.5°C), weight loss (24%)
224
HTLV-I(ACH) 3EF Lymphopenia (899 lymphocytes/l), hypothermia, lethargy, loss of consciousness 82
3EV Lymphopenia (995 lymphocytes/l) 216b
3FA Severe diarrhea, bloat, colonic lymphadenopathy 221b
3FN Hypothermia, weight loss (20%) 81
3EC Pneumonia, hypothermia (35°C), weight loss (28%), distended bladder, lymphopenia
(527 lymphocytes/l)
51
3DF None 129b
AD7D Arthropathy, diarrhea, thrombocytosis, hypothermia, dehydration, weight loss (17%) 35
AP1H Intermittent rash, bloat 87b
AP1T Diarrhea, extensive mesenteric lymphadenopathy 86b
AT4X Chronic severe rash 85b
a Weeks after first PTLV inoculation when death occurred.
b No life-threatening signs of disease at time of euthanasia.
FIG. 3. Radiographs of lower hind limbs of HTLV-I(ACH)-infected macaque AD7D showing loss of bone density and swelling of the left ankle.
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(TB7 and 3FN) had small foci of mononuclear cells and
neutrophils in the lamina propria.
PTLV-specific antibody responses
Macaques infected only with STLV-I(sm) generated
low to undetectable serum antibodies, as measured by
ELISA, throughout more than 4 years of follow-up (Fig.
4A). However, in one animal (TA7) serum antibody titers
increased several months before death, perhaps as a
result of increases in viral antigen and/or numbers of
infected cells. When antibody titers in six HTLV-I(ACH)-
infected macaques were evaluated, three animals had
serum antibody titers 10- to 100-fold higher than the
STLV-I(sm)-infected animals, whereas the other three
animals had levels of HTLV-I-specific antibodies that
were comparable to the STLV-I(sm)-infected group (Fig.
4B). Serum antibody titers were highest in most animals
at 2 to 3 weeks after the second inoculation of HTLV-
I(ACH), similar to a booster or anamnestic response after
vaccination. None of five CSF samples obtained at death
had detectable antibodies to PTLV.
Because the presence of antibodies recognizing
HTLV-I Tax protein is associated with high viral loads and
efficiency of transmission in infected humans and rabbits
(Kira et al., 1992; Major et al., 1995; Lydy et al., 1998),
circulating antibodies to Tax protein were evaluated by
immunoblot analysis. Assays were performed with ly-
sates of PTLV-infected cell lines or purified Tax protein
and sera obtained from PTLV-infected animals at multi-
ple times up to 1 year after infection, during the weeks
preceding death, and at necropsy (if available). None of
10 animals infected with either STLV-I(sm) or HTLV-
I(ACH) had detectable Tax-specific antibodies.
Quantification of PTLV-infected cells
Two methods were used to assess viral burdens. First,
it is known that the frequency with which infectious virus
can be amplified from cells ex vivo is related to viral
burden. Therefore, macaque PBMC were cocultured with
mitogen-activated human PBMC and the supernatants
were assayed for HTLV-I p19 Gag antigen. From the time
of initial infection until death, the ability to detect cell-free
PTLV in cultures of PBMC from individual macaques
infected only with STLV-I(sm) or HTLV-I(ACH) ranged
from 55.3 to 81.8% or 15.4 to 94.4%, respectively (data not
shown). At necropsy, regardless of whether macaques
were infected only with a PTLV or were coinfected with
SIV-PBj14-bcl1, production of cell-free PTLV in cocultures
FIG. 4. PTLV-specific serum antibody titers of pig-tailed macaques infected with STLV-I(sm) (A) or HTLV-I(ACH) (B).
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was limited primarily to PBMC and various lymph nodes;
less than 50% of the animals had detectable PTLV in
splenic tissue (Table 2). Tissues from those animals
infected only with a PTLV and that were found dead in
their cages were not available.
Second, numbers of infected lymphocytes in periph-
eral blood were determined by multiple independent
PCR-based limiting dilution assays (PLDA) using primers
specific for tax and env gene sequences. This assay
enables consistent detection of genomic DNA equivalent
to that in one MT2 cell. Proviral burdens in PBMC during
the first 6 weeks after infection varied from undetectable
using DNA from 600,000 cells to approximately 1100
copies in 106 cells (if one assumes 1 g is equivalent to
DNA from 150,000 cells) (Fig. 5); however, most values
were less than 50 copies in 106 cells. STLV-I(sm) proviral
DNA was detected in cells from only two of five ma-
caques, whereas HTLV-I(ACH) proviruses were detected
in five of seven macaques. At 9 weeks after infection,
copy numbers in STLV-I(sm)-infected animals appeared
to peak, but levels ranged from 4 to 3900 copies per 106
cells; the latter value is equivalent to one infected cell in
about 250 PBMC. In general, there was minimal variation
in proviral copy numbers from 12 to 87 weeks, the latest
times tested, nor was there any significant difference in
proviral burdens in animals infected with STLV-I(sm) ver-
sus HTLV-I(ACH). Furthermore, there was no correlation
between proviral copy numbers and PTLV-specific anti-
body titers throughout infection (Fig. 6).
TABLE 2
Presence of PTLV p19 Gag Antigen in Cultures of Tissues Obtained at Necropsy
Virus Macaque Weeksa
Tissueb
PBMC PLN MLN CLN Spleen Brain SpC CSF
HTLV-I 3EF 82 c      ND ND
3EC 51   ND ND    
3DF 129    ND  ND  
3EV 216   / ND  ND  
3FA 221   ND   ND  
AT4X 85    ND  ND ND 
AP1T 86    ND  ND ND 
AP1H 87    ND  ND ND 
STLV-I TA7 192       ND ND
TB7 111   ND ND   ND ND
TC1 224       ND 
STLV-I/SIV P8G 180 /      ND 
P9E 241    ND    ND
P010 199       ND ND
P003 146      ND ND ND
P020 233      ND  
P023 193       ND 
a Weeks after inoculation of HTLV-I(ACH) or STLV-I(sm).
b PLN, peripheral lymph node; MLN, jejunal mesenteric lymph node; CLN, colonic mesenteric lymph node; SpC, spinal cord; CSF, either fluid and
cells or cells pelleted from cerebrospinal fluid; ND, not done. Brain samples were taken from the cerebral cortex and/or cerebellum.
c Relative amounts of PTLV p19 Gag in culture supernatants reflect maximum optical density (OD) readings at 450 nm during approximately 7 weeks
of culture. , below cutoff value; , OD  0.3; , 0.3  OD  0.8; , 0.8  OD  1.5; , OD  1.5.
FIG. 5. PTLV proviral copy numbers in 106 PBMC from STLV-I(sm)-
and HTLV-I(ACH)-infected macaques (solid and open symbols, respec-
tively). Although five of the STLV-I(sm)-infected macaques were also
infected with SIV-PBj14-bcl1, values are provided only for the first 9
weeks, before inoculation of the second virus. Symbols with down
arrows indicate all PCRs on that sample were negative and, as a result,
the number of provirus copies is assumed to be less than the value
shown, as estimated by the total amount of DNA (and cell equivalents)
tested in all PCRs done on a particular sample.
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With respect to central nervous system (CNS) tissues,
virus was not detected in cultures of any samples from
the brain. In contrast, although spinal cord and cerebral
spinal fluid (CSF) from only a few macaques were eval-
uated, PTLV p19 Gag was detected in culture superna-
tants of either spinal cord or CSF from at least one
macaque. To confirm that PTLV entered the CNS, CSF
samples obtained at necropsy from 11 animals were
tested directly by ELISA for PTLV p19 Gag antigen. Of
macaques infected with HTLV-I(ACH) or STLV-I(sm)
alone, CSF from only two animals (3EC and AP1T) was
positive for HTLV-I(ACH) Gag antigen. However, CSF
samples from two (P020 and P023) of three macaques
coinfected with STLV-I(sm) and SIV-PBj14-bcl1 that were
tested were positive for p19 Gag antigen. Genomic DNA
was isolated from cerebral cortex and/or cerebellum
tissues from six PTLV-infected macaques and tested in
three independent nested PCR assays; all samples were
negative for PTLV proviral DNA. Likewise, genomic DNA
extracted from the cervical and thoracic spinal cords
from two PTLV-infected macaques was also negative.
Failure to detect proviral DNA in CNS tissues might have
occurred either because there were no cells harboring
proviruses or, more likely, because the number of such
cells was extremely low and none were in the specific
samples that were tested.
Cell-free virus
Miller et al. (1999) recently provided evidence for cell-
free HTLV-I transmission to rats using serum from HAM/
TSP patients. Therefore, plasma samples obtained at
various times between 6 and 191 weeks after inoculation
from nine HTLV-I(ACH)- or STLV-I(sm)-infected macaques
were tested by RT-PCR for the presence of cell-free
virions. Cell-free virus was not detected in any of the
plasma samples analyzed (data not shown).
PTLV tropism
To define the in vivo tropism of STLV-I(sm) and HTLV-
I(ACH) for lymphocyte subsets in pig-tailed macaques,
CD4 and CD8 T cells from peripheral blood were
sorted by flow cytometry after removing adherent and B
cells by panning. Genomic DNA from purified CD4 or
CD8 T cells was extracted and subjected to nested PCR
for amplification of PTLV tax and env sequences (Table
3). Using env primers, STLV-I(sm) proviral DNA in PBMC
was found with the same efficiency in both CD4 and
CD8 T cells. A combined total of 20 nested PCRs on six
different sorted CD4 and CD8 T cell populations ob-
tained from four infected pig-tailed macaques between
weeks 158 and 190 were done. Except for one CD4 T
cell sample, all nested PCRs for STLV-I(sm) env se-
quences were positive. In contrast, HTLV-I(ACH) proviral
sequences were detected less frequently. Primers for
both env and tax were used in 64 separate nested PCRs
for proviral DNA in CD4 and CD8 T cell populations
from 12 independent live cell sorts of PBMC from four
different macaques infected with HTLV-I(ACH). The per-
centage of positive nested PCRs for proviral DNA from
these animals was significantly less than that for STLV-
I(sm)-infected animals, indicating a lower number of lym-
phocytes containing proviruses. Of interest, with the ex-
TABLE 3
PTLV Tropism for Lymphocytes in Peripheral Blood of Infected
Pig-Tailed Macaques
Virus Macaque Weeksa T cellsb
Positive
PCRs (%)c
HTLV-I(ACH) 3FA 111, 114, 123, 165,
216
CD4 7/13 (53.8)
CD8 2/13 (15.4)
3EV 111, 114, 123, 165 CD4 1/11 (9.1)
CD8 0/11 (0)
3DF 58, 74 CD4 1/6 (16.7)
CD8 0/6 (0)
AD7D 2 CD4 2/2 (100)
CD8 0/2 (0)
STLV-I(sm) P9E 158, 190 CD4 2/3 (66.7)
CD8 3/3 (100)
P010 158, 190 CD4 3/3 (100)
CD8 3/3 (100)
P020 158 CD4 2/2 (100)
CD8 2/2 (100)
TA7 176 CD4 2/2 (100)
CD8 2/2 (100)
a Weeks after infection at time of live PBMC sorts.
b Purity of subpopulations from all animals was determined by flow
cytometry to be 97.5%.
c Results of all nested PCRs for all time points were combined and
are shown as the number of positive reactions/number of independent
nested PCRs. CD4 and CD8 subsets from HTLV-I(ACH)-infected
macaques were evaluated using env primers and for one reaction per
sample, tax primers; assays performed on samples from STLV-I(sm)-
infected macaques were done with env primers only.
FIG. 6. Lack of correlation between proviral copy number and virus-
specific antibody titers in macaques infected with STLV-I(sm) (solid
squares, solid line, upper r and P values) or HTLV-I(ACH) (open
squares, dashed line, lower r and P values).
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ception of two nested PCRs with DNA from PBMC from
macaque 3FA, only the CD4 cell populations from the
four HTLV-I(ACH)-infected animals were positive, sug-
gesting that HTLV-I(ACH) might have a more restricted
cellular tropism than STLV-I(sm).
DISCUSSION
The vast majority of HTLV-I-infected humans remain
asymptomatic carriers, with less than 5% of individuals
developing either ATL after a latent period of several
decades or HAM/TSP within months to years after infec-
tion (Hinuma et al., 1982; Yoshida et al., 1982; Gessain et
al., 1985; Rodgers-Johnson et al., 1985; Bartholomew et
al., 1986; Vernant et al., 1987). Similarly, although many
species of old-world nonhuman primates are infected
with STLV-I in the wild, cases of spontaneous lymphoma
in monkeys and baboons are relatively rare (Homma et
al., 1984; Voevodin et al., 1985; Tsujimoto et al., 1985,
1987; Noda et al., 1986; Sakakibara et al., 1986; McCarthy
et al., 1990; Fultz, 1994; Akari et al., 1998). Previous
studies involving experimental infection of nonhuman
primates with HTLV-I resulted in no evidence of lympho-
proliferative or neurologic disease (Nakamura et al.,
1986, 1987; Kazanji et al., 1997, 2000). However, Beilke et
al. (1996) reported development of polymyositis, arthritis,
myopathy, and uveitis in one of two rhesus macaques
inoculated with HTLV-I-infected cells. This earlier study
supports our results that establishment of persistent
infection with HTLV-I(ACH) in pig-tailed macaques might
provide a model for studying pathogenic events associ-
ated with HTLV-I infection.
The acute onset of morbidity with rapid death that was
observed in our cohort has not been described in PTLV-
infected macaques. However, relatively few macaques
have been experimentally infected with HTLV-I and none
with STLV-I. That 54% of the infected macaques died
within 4 12 years was unexpected since the percentages
of PTLV-infected humans and nonhuman primates that
develop disease are low and signs of disease usually
are not seen until many years after initial infection (Mur-
phy et al., 1989; Kaplan et al., 1990). A possible genetic
defect that increased disease susceptibility of macaques
in the present study seemed unlikely since some ani-
mals were from different suppliers and/or were obtained
in different calendar years. It is impossible, however, to
rule out an occult infection with another pathogen as the
cause of the morbidity and mortality we observed. If
another pathogen were involved, it more than likely was
an opportunistic infection, secondary to immunodefi-
ciency caused by PTLV infection. Furthermore, the find-
ing of only minimal pathology in gut tissue from these
animals indicates that the effects of another putative
pathogen in the gastrointestinal tract were minimal. An
alternative explanation for the observed disease syn-
drome in PTLV-infected pig-tailed macaques is that it is
linked to aberrant expression of proinflammatory and
other immunomodulatory cytokines that could lead to
chronic immune stimulation and/or immunodeficiency.
Both chronic activation of CD4 and CD8 lymphocytes
and failure of lymphocytes to respond to mitogens were
observed during a prospective study of a cohort of HTLV-
I(ACH)-infected macaques (to be reported elsewhere).
Although an outbreak of reactive arthritis induced by
Shigella flexneri in rhesus macaques at a primate center
was reported (Urvater et al., 2000), the other clinical
signs seen in these animals (muscle atrophy, self-limit-
ing diarrhea of only 1-day duration) differed from those in
the one macaque (AD7D) that developed arthritis in as-
sociation with HTLV-I(ACH) infection. AD7D was diag-
nosed with Shigella after its arrival at UAB in 1999;
however, after treatment this organism was not detected
in subsequent fecal smears. That macaque AD7D also
exhibited the rapid onset syndrome associated with hy-
pothermia and death in other PTLV-infected macaques
suggests that, if Shigella were involved in the develop-
ment of arthritis, it might have been reactivated from a
latent state as a result of AD7D’s immunocompromised
immune system (data not shown) and, therefore, was an
opportunistic pathogen. Of interest, the swelling in the
ankle joint and knee of macaque AD7D closely resem-
bled the inflammatory arthropathy seen in Tax-transgenic
mice (Iwakura et al., 1991; Saggioro et al., 1997). Also,
that p19 Gag antigen was found in bone marrow from
AD7D might be important since Saijo et al. (1999)
showed that bone marrow-derived cells were responsi-
ble for autoimmune arthritis in mice transgenic for the
HTLV-I pX region. Furthermore, the episode of thrombo-
cytosis that preceded end-stage disease and bloody
diarrhea in this animal is similar to conditions that occur
in humans with rheumatoid arthritis (Hutchinson et al.,
1976).
A comparison of the characteristics of disease asso-
ciated with PTLV infection of macaques and HTLV-I in-
fection of humans shows that there are similarities be-
tween the former and both ATL and HAM/TSP (Table 4).
Although only one macaque coinfected with both STLV-
I(sm) and SIV-PBj14-bcl1 had high levels of CD25 lym-
phocytes at time of death (55 weeks) (Fultz et al., 1999),
there appear to be more similarities overall with ATL, the
most notable of which include low serum antibody titers
and, in some individuals, low viral burdens, rash, lymph-
adenopathy, and bone marrow infiltration. However, the
presence of PTLV p19 Gag antigen in the CSF and the
observed bladder dysfunction, which is associated with
neurologic disease, are indicative of HAM/TSP. That fea-
tures of both ATL and HAM/TSP were observed in the
PTLV-infected macaques is suggestive evidence that the
two PTLV strains were linked to development of disease.
Clinical diagnosis of HAM/TSP in HTLV-I-infected hu-
mans is generally based on chronic paraparesis with
associated gait disturbances, lower extremity muscle
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weakness, and bladder and/or bowel dysfunction (Holls-
berg and Hafler, 1993; Osame et al., 1986). That we did
not observe muscle weakness in extremities or changes
in gait in PTLV-infected macaques is not surprising be-
cause monkeys do not walk or move like humans. In
addition, development of myelopathy is generally slow,
but progressive, and, therefore, would not be obvious
until it became severe. Confirmatory laboratory findings
for HAM/TSP include the presence of antibodies to
HTLV-I in blood and CSF and proviral DNA in infiltrating
lymphocytes (Hara et al., 1994; Puccioni-Sohler et al.,
2001). Infiltration of CD4 and CD8 lymphocytes and
monocytes into gray and white matter of the spinal cord
leads to degeneration of white matter, primarily in the
lower thoracic cord (Iwasaki, 1990; Umehara et al., 1993).
No evidence of demyelination was seen in sections of
the thoracic and lumbar spinal cords obtained from in-
fected macaques at necropsy. Peripheral nerves were
not examined for lesions. However, CNS tissues from all
animals, especially those that died early in these studies,
were not examined because we did not expect to see
such a high incidence of death with a possible PTLV
etiology. It is possible that areas of demyelination were
present in the spinal cords of the affected animals, but
that the specific tissue samples examined did not in-
clude any lesions. Relative to this point, during the late
stages of HAM/TSP in humans, the extent of inflamma-
tion as well as the number of CD4 T cells and the
amount of proviral DNA in the spinal cord often decrease
(Kubota et al., 1993, 1994; Umehara et al., 1993). Future
studies should include a more comprehensive and sys-
tematic evaluation of tissues during earlier times after
infection and of larger sections of spinal cords of in-
fected animals, perhaps with periodic MRI scans to de-
tect possible lesions.
In HTLV-I-infected humans, proviral burdens span a
broad range but, in general, individuals with HAM/TSP
have 10- to 100-fold more proviral copies than asymp-
tomatic carriers: approximately 5000 to 2  106 copies
compared to less than 10 to 1  105 copies per 106 cells,
respectively (Kira et al., 1991; Shinzato et al., 1991; Wattel
et al., 1992; Kubota et al., 1993; Manns et al., 1999;
Cesaire et al., 2001). In contrast, proviral burdens in ATL
patients or asymptomatic carriers can be high or low, at
levels comparable to those detected in the macaques,
which were consistently low overall, stabilizing between
approximately 10 and 100 copies per 106 PBMC. Thus,
HTLV-I disease that develops during long-term chronic
infections in humans can be associated with persistently
low viral loads, as it was in the macaques. In the ab-
sence of high viral burdens or opportunistic pathogens,
gastrointestinal disease, such as the chronic episodes of
diarrhea in the PTLV-infected macaques or in inflamma-
tory bowel disease, can be mediated by cytokines or, in
the absence of chronic inflammation, by such factors as
malabsorption or perturbations in motility (Adler et al.,
1993). Overall, there appeared to be no direct association
between viral burdens and disease in our model.
The levels of PTLV-specific antibodies observed in the
macaques are interesting when considered in associa-
tion with morbidity and mortality. The HTLV-I(ACH)-in-
fected macaques (3EC, 3EF, 3FN, AD7D) with the lowest
virus-specific antibody titers died in less than 2 years
after infection, suggesting that humoral responses might
protect against disease. Puccioni-Sohler et al. (1999)
found that in the CNS of HAM/TSP patients with high
viral loads, if there was no evidence of intrathecal syn-
thesis of HTLV-I antibodies, then clinical disease was
more serious and progressed more rapidly. No PTLV-
specific antibodies were detected in any macaque CNS
samples that were tested. Since PTLV are primarily cell-
associated viruses, functional properties of antibodies,
such as inhibition of syncytia formation and antibody-
dependent cellular cytotoxicity, should be evaluated. A
prospective study not only of antibodies but also of T
helper cell and cytotoxic T cell activity in PTLV-infected
animals might provide additional information about
whether specific immune responses are associated with
the fate of these animals. Tax-specific antibodies have
been documented in 50 to 60% of asymptomatic individ-
uals and 90% of HAM/TSP patients (Kamihira et al., 1989;
TABLE 4
Characteristics of PTLV Infections in Macaques and HTLV-I
Infections in Humans
Characteristic Macaque
Human
ATL HAM/TSP
Viral load Low Low to high High
Serum antibody
titers Low Low High
Antibodies to Tax No Yes Yes
Antibodies in CSF No No Yes
Rash/skin lesions Yes Yes No
Lymphadenopathy Yes Yes No
Bone marrow
infiltration Yes Yes Yes
Hypercalcemia No Yes No
Bladder dysfunction Yes No Yes
Sudden onset
disease Yes No/yes Yes
Spasticity/weakness
lower limbs ? No Yes
Lobulated nuclei in
lymphocytes Yes Yes Yes
Cellular infiltrate
CNS No No Yes
Loss of myelin No No Yes
Immunodeficiency Yes Yes Yes
Activated
lymphocytes Yes Yes Yes
Lymphopenia Yes No No
Note. No one characteristic is found in 100% of macaques or hu-
mans.
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Yokota et al., 1989; Shioiri et al., 1993), but we did not
detect Tax-specific antibodies in any of the PTLV-infected
macaques. Whether this finding was a result of the over-
all low antibody titers in the animals or a lack of sensi-
tivity of the assay is not known. It is probable, however,
that the natural history of PTLV infection in macaques is
inherently different from that in humans. This likelihood
is supported by the acute onset of disease and rapid
death we observed in 4 of the 10 HTLV-I(ACH)-infected
and two of the STLV-I(sm)-infected animals.
The pathogenesis of HTLV-I(ACH) and STLV-I(sm) in
pig-tailed macaques was essentially the same, but there
was an apparent difference between HTLV-I(ACH) and
STLV-I(sm) in the T cell subsets infected preferentially.
Although HTLV-I generally is considered to be tropic for
CD4 T cells, proviral DNA has been found in vivo not
only in CD8 T cells, albeit to a more limited extent, but
also in monocytes and other cell types (Richardson et al.,
1990; Koyanagi et al., 1993; Nagai et al., 2001). That only
2 of 32 (6.25%) PCRs on DNA from purified CD8, but 11
of 32 (34.4%) PCRs from CD4, lymphocytes from HTLV-
I(ACH)-infected macaques were positive for proviral DNA
is consistent with the human studies and with fewer cells
in the CD8 T cell population bearing proviruses. In
contrast, essentially all of the PCRs done with DNA from
the CD4 and CD8 lymphocytes from STLV-I(sm)-in-
fected macaques identified proviruses in both subsets.
These results agree with those from studies of nonhu-
man primates naturally infected with STLV-I; cell lines
established from PBMC of these animals generally have
a CD8 phenotype (Fultz, 1994).
In summary, we have described a nonhuman primate
model for persistent HTLV-I infection that appears to
induce a defined clinical syndrome in approximately 50%
of the animals within a reasonable observation period.
That the same clinical signs of disease were associated
with infection by two different PTLV strains in animals
inoculated at different times over a period of 5 years
supports the idea that the PTLVs were directly or indi-
rectly responsible for the observed morbidity and mor-
tality. This model, which is the first to describe disease
sequelae, including a reproducible, rapid onset syn-
drome, should be valuable for (i) defining humoral and
cellular immune responses to HTLV-I at all stages of
infection, (ii) determining the pathophysiology of HTLV-I,
and (iii) evaluating vaccine strategies for preventing in-
fection and/or disease.
MATERIALS AND METHODS
Animals and virus inoculations
Three pig-tailed macaques (M. nemestrina) were inoc-
ulated intravenously with 5 to 10  106 mangabey cells
(H11) persistently infected with STLV-I(sm), and 10 ani-
mals with pig-tailed macaque cells (PTMach) persis-
tently infected with HTLV-I(ACH). Ten additional animals
were inoculated with STLV-I(sm) and 9 weeks later with
SIV PBj14-bcl1, as described (Fultz et al., 1999). All ani-
mals were juvenile to young adults and were seronega-
tive for HTLV-I/STLV-I, simian immunodeficiency virus,
and simian retrovirus type D. Macaques were anesthe-
tized by intramuscular injection of ketamine (10 mg/kg),
and were euthanized by intravenous injection of pento-
barbital (75 mg/kg). CSF was collected by cervical or
lumbar puncture with a 22-gauge spinal needle while the
animals were anesthetized with ketamine and xylazine.
Physical examinations were done routinely when blood
was collected for virologic and hematologic evaluations.
After animals were euthanized with a lethal dose of a
pentobarbital solution, tissue samples were obtained,
immediately placed in 10% neutral buffered formalin, and
fixed for at least 1 week before being trimmed and
embedded in paraffin. Thin sections of the paraffin-em-
bedded tissues were cut and stained with hematoxylin
and eosin. Brain and spinal cord sections also were
stained with Luxol fast blue to detect myelin lipid. All
procedures were approved by the University of Alabama
at Birmingham Institutional Animal Care and Use Com-
mittee and were conducted in accordance with Animal
Welfare Act guidelines.
Serologic assays
PTLV-specific antibody titers were determined by us-
ing an HTLV-I Microelisa kit (Organon Technika, Durham,
NC). Antibody titers are expressed as the reciprocal of
the last serum dilution to give a positive optical density
(OD) reading at 450 nm.
For immunoblots, whole-cell lysates were prepared
from macaque T-cell lines F11 and P9B, both of which are
persistently infected with STLV-I(sm), and PTMach,
which is persistently infected with the molecular clone
HTLV-I(ACH) (Kimata et al., 1994). Equivalent amounts of
protein were loaded on each lane of a 10% polyacryl-
amide gel, separated by SDS–PAGE, and transferred to
nitrocellulose. Purified Tax protein, prepared as de-
scribed by Zhao and Giam (1991), was used to confirm
results obtained with cell lysates. Macaque sera were
diluted 1:100 or 1:500 for use as primary antibodies in
each assay. Positive control serum from an HTLV-I-in-
fected human was diluted 1:1500. Binding to PTLV pro-
teins was detected with horseradish peroxidase-conju-
gated goat anti-human secondary antibodies and en-
hanced chemiluminescence (Pierce).
Virus detection
Macaque PBMC, single-cell suspensions of various
lymph node and spleen tissues, whole CSF, or cells
pelleted from CSF were cultured with PHA-stimulated
normal human PBMC. Tissue fragments from the cere-
bral cortex, cerebellum, and spinal cord were minced
with scissors and cultured as above in RPMI 1640 with
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antibiotics, interleukin-2, and DEAE dextran. Every 4 to 5
days, culture supernatants were assayed for the pres-
ence of p19 capsid protein using a HTLV-I antigen cap-
ture kit, according to the manufacturer’s protocol (Cellu-
lar Products, Buffalo, NY). Cultures were monitored until
the OD reading reached maximum levels or for at least 7
weeks before being discarded as negative. All HTLV-I-
specific reagents and kits are highly cross-reactive with
the closely related STLV-I.
Semiquantitative nested PCR
PTLV proviral copy numbers in genomic DNA isolated
from lymphocytes in peripheral blood and mesenteric
lymph nodes were determined by PLDA (Rodrigo et al.,
1997). Genomic DNA was extracted from 2 to 10 106 cells
using a Qiagen Blood Amp DNA kit (Qiagen, Valencia, CA).
Samples containing 1 g DNA were serially diluted 1:5 or
1:2 and each dilution was assayed by nested PCR for PTLV
proviral sequences using primers specific for env and/or
tax genes. Nucleotide positions of first-round and nested
primers used to amplify a 379-bp region of the env gene are
numbered from position 1 in the STLV-I(sm) env gene se-
quence (Fultz et al., 1997): NF-2, 5-CAGCATCTTATTCA-
GACCCTTGTTCCC-3 (bases 302–328); NR, 5-TG-
GAAGCGCTAACGATGGGTAAAGGA-3 (bases 789–764);
NL, 5-CTTATACAGGAGCCGTCTCCAGCCC-3 (bases 368–
392); NQ, 5-GGATGGAACAGAGGCGTTGGGAGAG-3
(bases 746–722). The conditions for first- and second-round
nested PCR were those reported by Liska et al. (1997) with
somemodifications. Nested PCR to amplify a 159-bp region
of the tax gene was accomplished using the following
first-round primers, with nucleotide positions numbered
from position 1 of the STLV-I(sm) tax sequence: Tax-OF,
5-CACTTCCCAGGGTTTGGACA-3 (bases 7–26); Tax-OR,
5-GGGTGGAATGTTGGGGGTTG-3 (bases 310–291).
Nested primers SK43 and SK44 were described elsewhere
(Kubota et al., 1994). Proviral copy numbers and standard
errors were calculated and analyzed using the results from
multiple independent PLDA and the QUALITY program (Ro-
drigo et al., 1997). The sensitivity of the assay was as-
sessed using MT2 cellular DNA; the nested PCR assay
detected proviral DNA in one cell, which can harbor up to
eight complete and defective proviruses (Morozov and
Weiss, 1999).
RT-PCR
Plasma samples from PTLV-infected macaques were
clarified by centrifugation; the supernatants then were
passed through 0.45-m filters and ultracentrifuged for
1 h at 47,000 rpm. Pellets were resuspended in buffer
and viral RNA was extracted using a QiaAmp vRNA kit
(Qiagen). cDNA synthesis was performed with random
hexamer primers (Advantage RT-for-PCR kit; Clontech
Laboratories Inc.; Palo Alto, CA). STLV-I(sm) env se-
quences were amplified from cDNA by nested PCR using
primers NF-2/NR and NL/NQ, as described above.
Purification of CD4 and CD8 T cells
PBMC from PTLV-infected macaques were depleted of
adherent and B cell populations by incubation of cells for
2 h at 37°C in 100-mm tissue culture dishes coated with
rabbit anti-human Ig. Nonadherent cells were removed
by gentle pipetting, stained with anti-CD4-PE and anti-
CD8-FITC antibodies (Becton–Dickinson), and sorted live
into CD4 and CD8 T cell subsets on a FACStarPLUS flow
cytometer. The purity of the sorted T cell populations was
determined by flow cytometry using the same antibodies.
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